The peroxisome proliferator-activated receptor gamma (PPARG) is a nuclear receptor superfamily member that plays a critical role in adipogenesis, glucose metabolism, and inflammatory responses. As a ligand-activated transcription factor, PPARG regulates gene expression by binding to specific DNA response elements, often forming heterodimers with retinoid X receptors (RXRs). Its involvement in metabolic homeostasis has made it a key target for studying obesity, diabetes, and atherosclerosis. PPARG antibodies are essential tools for detecting and quantifying PPARG protein levels in research applications such as Western blotting, immunohistochemistry (IHC), and chromatin immunoprecipitation (ChIP). These antibodies are typically raised against specific epitopes of the human PPARG protein, with common immunogen regions including the N-terminal domain or ligand-binding domain. Validation steps, such as knockout cell line controls, are crucial to confirm specificity due to potential cross-reactivity with related proteins. Researchers use PPARG antibodies to investigate its expression patterns in tissues, interaction with co-regulators, and dysregulation in diseases like cancer, where PPARG may act as both an oncogene and tumor suppressor depending on context. Commercial PPARG antibodies are available from multiple suppliers, with host species including rabbit, mouse, and goat, often conjugated to markers like HRP or FITC for detection flexibility.